Key result
Hydralazine-nitrate benefits Black HFrEF patients and those intolerant to standard therapy, despite ACE inhibitor inferiority.
Why the study?
Combined hydralazine-nitrate has an avenue in the management of HFrEF, and exploring this pharmacotherapy aims to facilitate its clinical utility.
Does combined hydralazine-nitrate improve outcomes in subjects with heart failure with reduced ejection fraction?
Does combined hydralazine-nitrate improve outcomes in subjects with heart failure with reduced ejection fraction?
Combined hydralazine-nitrate remains a useful alternative therapy in HFrEF for Black patients or those with contraindications to first-line RAS inhibitors, despite being inferior to ACE inhibitors.
Answers are grounded in this paper and cite their sources.
Supports hydralazine-nitrate in select HFrEF subgroups; leaves open positioning versus contemporary GDMT.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Elnour et al. (2023) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Combined hydralazine-nitrate vs. Placebo or ACE inhibitors was evaluated. Combined hydralazine-nitrate provides clinical benefits in patients with heart failure with reduced ejection fraction, particularly in Black subjects and those with contraindications to standard therapy, despite being inferior to ACE inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: